3H9-KGDEVD-MMAE / Pharosgen - LARVOL DELTA

Tumor endothelial cell and cancer cell targeting anti-PRND antibody-drug conjugate to treat hypervascular tumors such as glioblastoma and sarcomas (AACR 2026) - "The resulting antibody-drug conjugate, 3H9-KGDEVD-MMAE, is a homogeneous ADC (DAR = 8) free of soluble aggregates...In preclinical models of glioblastoma, sarcoma, and renal cell carcinoma (RCC) - hypervascular malignancies with limited ADC options, anti-PRND ADC induced extensive and durable tumor regressions without systemic toxicity. Collectively, these findings establish anti-PRND ADC as a next-generation vascular-disrupting ADC, integrating endothelial docking with apoptosis-triggered drug amplification for potent and selective control of highly vascularized tumors.Acknowledgments: This research was supported by the Korea Drug Development Fund (HN21C0264) funded by the Ministry of Science and ICT and the National Research Foundation of Korea (NRF) grant (2020R1A2C2015026) funded by the Korea government (MSIT)."

ADC • Brain Cancer • Genito-urinary Cancer • Glioblastoma • Oncology • Renal Cell Carcinoma • Sarcoma • Solid Tumor • CASP3 • CASP7 • CTSB